Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Positron Emission Tomography Imaging of Participants With Known or Suspected Neuroendocrine Tumours Using 64Cu SARTATE: A Multi-Centre, Single Arm, Non-Randomised, Blinded-Review, Phase II Study

Next Previous
Trial Profile

Positron Emission Tomography Imaging of Participants With Known or Suspected Neuroendocrine Tumours Using 64Cu SARTATE: A Multi-Centre, Single Arm, Non-Randomised, Blinded-Review, Phase II Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 64Cu-MeCOSar-Octreotate (Primary)
  • Indications Neuroendocrine tumours
  • Focus Diagnostic use
  • Acronyms DISCO
  • Sponsors Clarity Pharmaceuticals

Most Recent Events

  • 05 Jun 2025 Positive topline results presented in the Clarity Pharmaceuticals media Release.
  • 12 Feb 2025 Status changed from active, no longer recruiting to completed.
  • 28 Nov 2024 According to an Clarity Pharmaceuticals media release, the last patient has completed their final assessment in this trial. Final results from the DISCO study to be available in the first half of 2025, which will inform the design of registrational Phase III trial in this indication.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top